Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics"
Bovijn J., Krebs K., Chen CY., Boxall R., Censin JC., Ferreira T., Pulit SL., Glastonbury CA., Laber S., Millwood IY., Lin K., Li L., Chen Z., Milani L., Smith GD., Walters RG., Mägi R., Neale BM., Lindgren CM., Holmes MV.
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.